BCL2L1 and chordoma: These were miR-608, which has potential binding sites in the 3′UTR of EGFR and Bcl-xL mRNAs (which are overexpressed in almost all chordoma tumors) and miR-34a which is predicted to target MET (expressed in up to 100% of chordomas) [21]–[23].